BioMarin Pharmaceutical (BMRN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who welcomed participants and outlined the virtual format and rules of conduct.
The Secretary confirmed the availability of the stockholder list and notice of meeting, and the Inspector of Election was appointed.
A quorum was established with 90.96% of shares represented, allowing business to proceed.
Board and executive committee updates
Ten directors were nominated for election to serve until the next annual meeting or until successors are elected.
Shareholder proposals
Four proposals were presented: election of directors, ratification of KPMG LLP as auditor, advisory vote on executive compensation, and approval of an amendment to the 2017 Equity Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BioMarin Pharmaceutical
- Amicus integration, VOXZOGO growth, and pipeline expansion fuel rare disease leadership.BMRN
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 20% to $990M; guidance raised, but net income fell on integration costs.BMRN
Q2 2026 - Strong execution, pipeline advances, and global expansion drive growth and innovation.BMRN
Morgan Stanley 23rd Annual Global Healthcare Conference - Q1 2026 revenue rose to $766M as Amicus was acquired, but net income fell on higher costs.BMRN
Q1 2026 - Proxy covers director elections, equity plan amendment, strong 2025 results, and ESG progress.BMRN
Proxy filing - 2025 revenue up 13% to $3.22B, with VOXZOGO and enzyme therapies driving global growth.BMRN
Q4 2025 - $4.8B acquisition adds two rare disease therapies, accelerating growth and portfolio diversity.BMRN
M&A Announcement - Q2 revenue up 20% to $712M, guidance raised, and VOXZOGO demand surged.BMRN
Q2 2024 - Q3 revenue up 28% with doubled net income and raised guidance, led by VOXZOGO growth.BMRN
Q3 2024